Acute-phase gene expression correlates with intrahepatic tumor necrosis factor-α abundance but not with plasma tumor necrosis factor concentrations during sepsis/systemic inflammatory response syndrome in the rat

Critical Care Medicine

Volumn 24, Issue 12, 1996, Pages 1947-1952

  Andrejko, Kenneth M ^a   Deutschman, Clifford S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acute phase response; critical illness; cytokines; immunohistochemistry; liver; sepsis; stress; systemic inflammatory response syndrome; tumor necrosis factor; tumor necrosis factor ; 1 acid glycoprotein

Indexed keywords

CYTOKINE; INTERLEUKIN 1; OROSOMUCOID; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ARTICLE; CRITICAL ILLNESS; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; SEPSIS; STRESS;

EID: 0029856112     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199612000-00004     Document Type: Article

References (59)

1. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334:1717-1725
2. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355-357
3. Girardin E, Grau GE, Dayer JM, et al: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319:397-400
4. Fink MP: Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections. Crit Care Med 1995; 23: 989-991
5. Beutler B, Milsark IW, Cerami AC: Cachectin/tumor necrosis factor: Production, distribution and metabolic fate in vivo. J Immunol 1985; 135:3972-3977
6. Beutler B, Milsark IW, Cerami A: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-871
7. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal endotoxemia. Nature 1987; 330:662-664
8. Bone RC: The pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469
9. Bagby GJ, Plessala KJ, Wilson LA, et al: Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-88
10. Lundblad R, Sandven P, Giercksky K-E: The physical nature of a large bowel perforation predicts severity of the subsequent inflammatory response. Shock 1995; 3:455-461
11. Hadjiminas DJ, McMasters KM, Peyton JC, et al: Tissue tumor necrosis factor mRNA expression following cecal ligation and puncture or intraperitoneal injection of endotoxin. J Surg Res 1994; 56:549-555
12. McMasters KM, Peyton JC, Hadjiminas DJ, et al: Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture. Cytokines 1994; 6:530-536
13. Schlag G, Redl H, Davies J, et al: Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 1994; 2:10-18
14. Porat R, Paddock HN, Schwaitzberg SD, et al: Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis. Crit Care Med 1995; 23:1080-1089
15. Givner LB, Gray L, O'Shea TM: Antibodies to tumor necrosis factor-α: Use as adjunctive therapy in established group B streptococcal disease in newborn rats. Pediatr Res 1995; 38:551-554
16. Windsor ACJ, Mullen PG, Walsh CJ, et al: Delayed tumor necrosis factor-α blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental Gram-negative sepsis. Arch Surg 1994; 129:80-89
17. Christman JW, Holden EP, Blackwell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 1995; 23:955-963
18. Espat NJ, Cenden JC, Beierle EA, et al: PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J Surg Res 1995; 59:153-158
19. Fisher CJ Jr, Opal SM, Dhainaut J-F, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
20. Dhainaut J-F, Vincent J-L, Richard C, et al: CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune responses, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995; 23:461-469
21. Abraham EA, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995; 273:934-941
22. Echtenacher B, Falk W, Mannel DN, et al: Requirement for endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-3766
23. Eskandari MK, Bolgos G, Miller C, et al: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-2727
24. Remick D, Manohar P, Bolgos G, et al: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality but not the lethality of cecal ligation and puncture. Shock 1995; 4:89-95
25. Stack AM, Saladine RA, Thompson C, et al: Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med 1995; 23:1512-1518
26. Hadjiminas DJ, McMasters KM, Peyton JC, et al: Passive immunization against tumor necrosis factor in interleukin-1 fails to reduce lung neutrophil sequestration in chronic sepsis. Shock 1994; 2:376-380
27. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994; 15: 74-80
28. Deutschman CS, Haber BA, Andrejko K, et al: Increased expression of cytokine induced neutrophil chemoattractant (CINC) in septic rat liver. Am J Physiol 1996; 271:R593-R600
29. Deutschman CS, De Maio A, Buchman TG, et al: Sepsis-induced alterations in phosphoenolpyruvate carboxykinase expression: The role of insulin and glucagon. Circ Shock 1993; 40:295-302
30. Deutschman CS, De Maio A, Clemens MG: Sepsis-induced attenuation of glucagon and 8-BrcAMP modulation of the phosphoenolpyruvate carboxykinase gene. Am J Physiol 1995; 38:R584-R591
31. Chomczynski P, Sacchi N: A single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159
32. Feinberg AP, Vogelstein B: A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132:6-13
33. Moscovitz H, Shofer F, Mignott H, et al: Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994; 22:1102-1107
34. Fey GH, Hocke GM, Wilson DR, et al: Cytokines and the acute phase response in the liver. In: The Liver: Biology and Pathobiology. Third Edition. Arias IM, Boyer JL, Fausto N, et al (Eds). New York, Raven Press, 1994, pp 113-143
35. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock A review of laboratory models and a proposal. J Surg Res 1980; 29:189-210
36. Chensue SW, Terebuh PD, Remick DG, et al: In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Am J Pathol 1991; 138:395-402
37. Bradding P, Roberts JA, Britten KM, et al: Interleukin-4, -5, -6 and tumor necrosis factor-α in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-480
38. Vanhee D, Gosset P, Marquette CH, et al: Secretion and mRNA expression of TNF-α and IL-6 in the lungs of pneumoconiosis patients. Am J Respir Crit Care Med 1995; 152:298-306
39. Piguet PF, Ribaux C, Karpuz V, et al: Expression and localization of tumor necrosis factor-α and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143:651-655
40. Kapadia S, Lee J, Torre-Amione G, et al: Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96:1042-1052
41. Roby KF, Hunt JS: Mouse endometrial tumor necrosis factor-α messenger ribonucleic acid and protein: Localization and regulation by estradiol and progesterone. Endocrinology 1994; 135:2780-2789
42. Stallmach T, Hebisch G, Joller-Jemelka HI, et al: Cytokine production and visualized effects in the maternal fetal unit. Quantitative and topographic data on cytokines during intrauterine disease. Lab Invest 1995; 73:384-392
43. Roessler K, Suchanek G, Breitschopf H, et al: Detection of tumor necrosis factor-α protein and messenger RNA in human glial brain tumors: Comparison of immunohistochemistry with in situ hybridization using molecular probes. J Neurosurg 1995; 83:291-297
44. Miles DW, Happerfield LC, Naylor MS, et al: Expression of tumor necrosis factor (TNFα) and its receptor in benign and malignant breast tissue. Int J Cancer 1994; 56:777-782
45. Hicks DG, Gokan T, O'Keefe RJ, et al: Primary lymphoma of bone: Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer 1995; 75:973-980
46. Wasse I, Bergholz M, Iglauer A, et al: Heterogeneity of tumor necrosis factor production in renal cell carcinoma. Eur J Cancer 1992; 28A:1660-1664
47. Neale TJ, Ruger BM, Macaulay H, et al: Tumor necrosis factor-α is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995; 146:1444-1454
48. Pickvance EA, Oegema TR Jr, Thompson RC Jr: Immunolocalization of selected cytokines and proteases in canine articular cartilage after transarticular loading. J Orthop Res 1993; 11:313-323
49. Przemioslo RT, Kontakou M, Nobili V, et al: Raised pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-α in coeliac disease mucosa detected by immunohistochemistry. Gut 1994; 35:1398-1403
50. Hussain MJ, Lau JYN, Williams R, et al: Hepatic expression of tumour necrosis factor-α in chronic hepatitis B virus infection. J Clin Pathol 1994; 47: 1112-1115
51. Murch SH, Braegger CP, Walker-Smith JA, et al: Location of tumor necrosis factor-α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34:1705-1709
52. Ayala A, Deol ZK, Lehman DL, et al: Does endotoxin play a major role in inducing the depression of macrophage function during polymicrobial sepsis? Arch Surg 1995; 130:1178-1185
53. Meduri GU, Kohler G, Headley S, et al: Inflammatory cytokines in the BAL of patients with ARDS: Persistent elevation over time predicts poor outcome. Chest 1995; 108:1303-1314
54. Giroir BP, Johnson JH, Brown T, et al: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992; 90:693-698
55. Enayati P, Brennan MF, Fong Y: Systemic and liver cytokine activation: Implications for liver regeneration and posthepatectomy endotoxemia and sepsis. Arch Surg 1994; 129:1159-1164
56. Rice NR, Ernst MK: In vivo control of NF-κB activation by IκBα. EMBO J 1993; 12:4685-4695
57. Tutor JD, Mason CM, Dobard E, et al: Loss of compartmentalization of alveolar tumor necrosis factor after lung injury. Am J Respir Crit Care Med 1994; 149:1107-1111
58. Gearing AJH, Beckett P, Christodoulou M, et al: Matrix metalloproteinases and processing of pro-TNF-α. J Leukoc Biol 1995; 57:774-777
59. Witthaut R, Farhood A, Smith CW, et al: Complement and tumor necrosis factor-α contribute to Mac-1 (CD11b/ CD18) up-regulation and systemic neutrophil activation during endotoxemia in vivo. J Leukoc Biol 1994; 55:105-111